Last updated: 23 September 2026.
Hempncare.com publishes educational content about hemp, CBD, and cannabinoids. Given how much confusion and inconsistent information exists in this space, we think it’s worth being explicit about how we approach research, what standards we hold ourselves to, and where our limitations are.
What we are, and what we’re not
We are an educational publisher, not a medical provider, not a manufacturer, and not a testing laboratory. Nothing on this site constitutes medical advice, and we say so explicitly throughout our content because we mean it, not as a legal formality. Our role is to synthesize publicly available research, regulatory information, and product-category knowledge into content that helps readers ask better questions of their own doctors and make more informed purchasing decisions.
How we approach evidence
| Evidence type | How we treat it |
|---|---|
| Peer-reviewed human clinical trials | Highest weight; we specify sample size and context where relevant |
| FDA-reviewed pharmaceutical data (e.g. Epidiolex) | Treated as strong evidence, clearly distinguished from over-the-counter product claims |
| Animal and preclinical studies | Reported as preliminary; we avoid extrapolating directly to human outcomes without flagging the gap |
| Mechanism-based reasoning (e.g. shared liver enzyme pathways) | Presented as plausible and reasonable caution, not confirmed clinical fact, unless supported by case reports or trials |
| Anecdotal or user-reported effects | Noted as such explicitly; never presented as equivalent to clinical evidence |
Our specific commitments
- We distinguish “not established” from “disproven.” A lot of cannabinoid research is genuinely early-stage. We try to say clearly when evidence is thin rather than either overstating confidence or implying something doesn’t work when it simply hasn’t been well studied yet.
- We flag when we’re extrapolating. If a claim rests on general pharmacological reasoning rather than a study of the exact combination or condition in question, we say so.
- We update content when the picture changes. Cannabinoid research and regulation move quickly. Pages carry a “last updated” date, and we revise content when new information warrants it rather than leaving outdated claims standing.
- We correct errors we find. When we identify outdated, duplicated, or inaccurate content on this site, we fix or consolidate it rather than leaving it live for search traffic.
- We don’t make treatment claims for unapproved uses. Outside of Epidiolex’s specific FDA-approved indication, we do not claim CBD or other cannabinoids treat or cure any medical condition.
Why so much of our content ends with “talk to your doctor”
This isn’t boilerplate we add reflexively. Cannabinoids have a genuinely broad drug interaction profile, primarily through the CYP3A4 liver enzyme pathway, and individual health circumstances vary enormously. A recommendation that’s reasonable for a healthy adult on no medications can be actively unwise for someone on blood thinners, immunosuppressants, or psychiatric medication. We’d rather consistently point toward professional guidance than give confident-sounding advice that doesn’t account for an individual reader’s actual medical situation.
What we do when evidence is genuinely mixed or absent
We say so directly. Several of our articles on specific conditions, migraines, ADHD, restless leg syndrome, and others, conclude that current evidence doesn’t support strong claims, even though those are commonly searched topics where confident-sounding answers would likely perform better in search traffic terms. We think accuracy matters more than that, and we’d rather a reader leave with a correctly calibrated sense of uncertainty than a false sense of confidence.
Corrections and feedback
If you believe something on this site is inaccurate, outdated, or misleading, we want to know. Content on cannabinoids and hemp changes as research develops, and we treat correction requests as a normal, ongoing part of maintaining an accurate resource rather than an inconvenience.
